Articles

See what's in this issue of The Oncology Nurse-APN/PA. Read More ›

An interactive text messaging tool to assess adherence to adjuvant endocrine therapy for breast cancer and to deliver direct communication to providers was found helpful by the majority of patients. Read More ›

Both abiraterone and enzalutamide are approved by the US Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Both drugs have different mechanisms of action and different adverse event profiles, but there are limited data comparing them directly. Read More ›

Regular use of aspirin appeared to reduce the risk for dying from lethal prostate cancer in a large observational study reported at the 2016 Genitourinary Cancers Symposium. Read More ›

Docetaxel added to androgen-deprivation therapy (ADT) improves survival for men with metastatic hormone-sensitive prostate cancer (mHSPC), as shown by the pivotal ECOG 3805 CHAARTED trial. Read More ›

Men with low-risk prostate cancer are typically offered management with active surveillance, which entails regular office visits, digital rectal exam, MRI scans, prostate-specific antigen (PSA) testing, and prostate biopsy at physician-specified intervals. Read More ›

Multiplex genetic testing in BRCA1/2-negative cancer patients with in-person genetic counseling allows informed decision-making while decreasing short-term anxiety, according to data presented at the 2015 San Antonio Breast Cancer Symposium. Read More ›

An open-label, randomized, phase 2 study evaluated the all-oral triplet combination of ixazomib (an orally administered proteasome inhibitor) plus cyclophosphamide (at 2 different doses) and low-dose dexamethasone (ICd) as a 12-month induction therapy in previously untreated, transplant-ineligible patients with multiple myeloma (MM). Read More ›

Presence of cytogenetic abnormalities (CAs) is considered to be an important prognostic factor in patients with multiple myeloma (MM), with some evidence suggesting that bortezomib-based combinations may overcome the poor prognosis associated with CAs, such as t(4;14), t(14;16), or deletion of 17p (del [17p]). Read More ›